Loading
BI
BIO Stock: price and insider trades · Australia
AU·Mcap A$92.3M
No insider purchase over the last 90 days. The latest was filed 25 Jun 2026.
BIO: what insiders have been doing
Every trade that managers of BIO disclose to ASX is tracked on this page. Over the twelve months to 18 October 2026, 3 filings were filed, from 1 insider.
Only purchases show up on the open market, 3 purchases in all worth €48k, filed by 1 insider. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive. Biggest ticket of the year: €16k, bought by Blair Vega Norfolk and made public on 3 June 2026.
With 3 filings in twelve months, the company is in line with the median of 3 filings across the 2,222 companies we follow on the same exchange. Over the whole record (from 2026), the tally stands at 3 purchases and no sales.
The clock since the last published purchase (25 June 2026) now reads 114 days. Publication is fast: at least half of the trades appear on ASX on the same day. This delay matters because a trade only becomes useful information once it is public.
Source: insider filings from ASX. Past trades are no guide to future returns.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€48,083
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleBlair Vega Norfolk3 buys
Since the insiders bought
- +68.8%Entry A$0.24 · Close 16 Oct 2026 A$0.41
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate BIO Strong Buy (bullish), based on 1 analysts. Average price target: A$0.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,904 of 24,148 companies
47.2
score / 100
Value31
Quality63
FCF yld-0.2%
Earn yld-1.8%
EV/EBITDA·
ROE51%
Gross mgn61%
Net mgn-13%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended June 2024 · cache
A$0.41
Analyst consensus
1 analystsStrong buy
A$0.75Target A$0.75(+85%)A$0.75
Income statement
RevenueA$13M
Gross profitA$7.9M61% margin
EBITDA-A$1.3M-10% margin
Net income-A$1.7M15.1% margin
Valuation
PER (trailing)20.3x
PER (forward)16.9x
P/Book9.9x
Beta0.99
Balance sheet & cash
Market capA$92.3M
Total debtA$1.3M
Free Cash Flow-A$185.4k
Debt / Equity32%
Profitability & ownership
ROE51.3%
ROA2.6%
% insiders36.6%
% institutions1.0%
Last declaration on 25 June 2026
Declarations3 total
100,000 shares@ A$0.250331.6% of flowShareASXASX:2924-03104176-3A696021
Canonical exit: 23 Sept 2026 (T+90)
100,000 shares@ A$0.270334.1% of flowShareASXASX:2924-03099106-3A695079
Canonical exit: 8 Sept 2026 (T+90)
102,000 shares@ A$0.263134.3% of flowShareASXASX:2924-03097080-3A694717
Canonical exit: 1 Sept 2026 (T+90)
3 of 3 declarations
About BIO
BIO is a company listed on the XASX market, specializing in the biotechnology sector. It focuses on developing innovative health solutions.
